Effect of intrapulmonary injection of processed serum derived from covid-19 patients in reduction of pulmonary complications

Phase 2

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20091012002582N21
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

intubated covid-19 patients

Exclusion Criteria

transplantation history
malignancy
thoracic surgery
active bacterial infection
autoimmune disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oxygenation. Timepoint: During 10 days from intratracheal injection. Method of measurement: Arterial blood gas analysis.

Secondary Outcome Measures

Name	Time	Method
Change in CO2. Timepoint: During 10 days after intratracheal intubation. Method of measurement: Analysis of arterial blood gases.;Respiratory compliance. Timepoint: During 10 days after intratracheal intubation. Method of measurement: Ventilator.;Airway resistance. Timepoint: During 10 days after intratracheal intubation. Method of measurement: Ventilator.